Accuray Incorporated (ARAY) Scheduled to Post Quarterly Earnings on Tuesday
Accuray Incorporated (NASDAQ:ARAY) is scheduled to be announcing its earnings results after the market closes on Tuesday, October 24th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Tuesday, August 22nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.05). Accuray had a negative net margin of 7.71% and a negative return on equity of 61.62%. The firm had revenue of $112.09 million for the quarter, compared to the consensus estimate of $112.00 million. During the same quarter in the prior year, the firm earned ($0.09) earnings per share. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, analysts expect Accuray to post $-0.15 EPS for the current fiscal year and $-0.05 EPS for the next fiscal year.
Shares of Accuray Incorporated (NASDAQ ARAY) opened at 4.20 on Tuesday. The company’s 50 day moving average price is $4.23 and its 200 day moving average price is $4.34. Accuray Incorporated has a 52-week low of $3.60 and a 52-week high of $6.00. The company’s market capitalization is $349.35 million.
In other Accuray news, COO Kelly Londy sold 99,136 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total transaction of $420,336.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.90% of the stock is currently owned by company insiders.
Several analysts have issued reports on ARAY shares. BidaskClub cut Accuray from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research cut Accuray from a “hold” rating to a “strong sell” rating in a research report on Monday, July 24th. Jefferies Group LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Accuray in a research report on Friday, June 30th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $5.00 target price on shares of Accuray in a research report on Thursday, August 24th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research report on Thursday, August 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. Accuray presently has an average rating of “Hold” and a consensus target price of $6.00.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.